Disease · MONDO_0005480

contact dermatitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. contact dermatitis. Diseases, record MONDO_0005480. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005480

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: contact dermatitis; Open Targets
Open Targets ID: MONDO_0005480; Open Targets
Disease Ontology: DOID:2773; Disease Ontology
MeSH: D003877; MeSH
NCI Thesaurus: C26743; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 18 drugs, from DailyMed and TTD; Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
BENTOQUATAM	CHEMBL1201446		Approval	TTD	1	0	0	Drugs and targets
FLUMETHASONE PIVALATE	CHEMBL1200877	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
BETAMETHASONE VALERATE	CHEMBL1497	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISOLONE ACETATE	CHEMBL1152	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	11	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
IL12B	Interleukin-12	2	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Phase 2/3	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	2	Interleukin-23 inhibitor	Phase 2/3	https://conductscience.org/library/genes/51561	Drugs and targets
IL12A	Interleukin-12	1	Interleukin-12 inhibitor	Phase 2/3	https://conductscience.org/library/genes/3592	Drugs and targets
IL1B	Interleukin-1 beta	1	Interleukin-1 beta inhibitor	Phase 2/3	https://conductscience.org/library/genes/3553	Drugs and targets
IL4R	Interleukin-4 receptor subunit alpha	1	Interleukin-4 receptor subunit alpha antagonist	Phase 2/3	https://conductscience.org/library/genes/3566	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit antagonist	Phase 2/3	https://conductscience.org/library/genes/3570	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 2/3	https://conductscience.org/library/genes/7124	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00929981	A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients		80	2011-12-26	Dermatitis, Contact	METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT01011621	Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis	Phase 3	170		Dermatitis, Atopic, Dermatitis, Contact, Dermatitis, Seborrheic, Psoriasis	BETAMETHASONE VALERATE, PREDNISOLONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT05535738	Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation	Phase 2/3	45		Skin Inflammation, Allergic Contact Dermatitis	ADALIMUMAB, BETAMETHASONE VALERATE, CANAKINUMAB, DUPILUMAB, FLUTICASONE PROPIONATE, GUSELKUMAB, SARILUMAB, TRIAMCINOLONE ACETONIDE, USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01736670	An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses	Not applicable	30		Acute Steroid Responsive Dermatoses, Chronic Steroid Responsive Dermatoses	TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005480

GET https://conductscience.org/api/diseases/v1/MONDO_0005480/drugs

API reference For AI assistants